Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

PUBLICATION DATE

4 results
Display

Aflibercept Treatment for Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy Refractory to Anti-vascular Endothelial Growth Factor

Moon DR, Lee DK, Kim SH, You YS, Kwon OW

PURPOSE: To report the results of switching treatment to vascular endothelial growth factor (VEGF) Trap-Eye (aflibercept) in neovascular age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV) refractory to anti-VEGF...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Sterile Inflammation after Intravitreal Injection of Aflibercept in a Korean Population

Kim JY, You YS, Kwon OW, Kim SH

PURPOSE: To report the frequency and clinical features of sterile inflammation after intravitreal aflibercept injection in a Korean population. METHODS: A single-center, retrospective study was performed in patients who received intravitreal...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Protective effects of transduced Tat-DJ-1 protein against oxidative stress and ischemic brain injury

Jeong HJ, Kim DW, Kim MJ, Woo SJ, Kim HR, Kim SM, Jo HS, Hwang HS, Kim DS, Cho SW, Won MH, Han KH, Park J, Eum WS, Choi SY

  • KMID: 1506222
  • Exp Mol Med.
  • 2012 Oct;44(10):586-593.
Reactive oxygen species (ROS) contribute to the development of a number of neuronal diseases including ischemia. DJ-1, also known to PARK7, plays an important role in transcriptional regulation, acting as...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Angiopoietin-1 variant, COMP-Ang1 attenuates hydrogen peroxide-induced acute lung injury

Kim SR, Lee KS, Park SJ, Min KH, Lee KY, Choe YH, Hong SH, Koh GY, Lee YC

Reactive oxygen species (ROS) play a crucial role in acute lung injury. Tissue inflammation, the increased vascular permeability, and plasma exudation are cardinal features of acute lung injury. Angiopoietin-1 (Ang1)...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr